BIOMAT Database Logo BIOMAT Database Logo

Low molecular weight heparin versus standard heparin. A long-term study in hemodialysis and hemofiltration patients. 1990

J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Department of Nephrology, Medical University Hospital Göttingen, West Germany.

The influence of low molecular weight (LMW) heparin (Braun 21-23, Mulsungen, West Germany) and unfractionated standard heparin (SH) on blood clotting and other routine laboratory parameters was investigated in a 30 week cross-over study in 30 hemodialysis patients. The LMW heparin dose necessary (anti FXa-activity) for effective anticoagulation was two thirds of the standard heparin dose. Using these doses, both substances displayed identical antithrombotic effects. Complications were not seen in either group. PTT and thrombin time were only marginally effected by LMW heparin, whereas they were markedly prolonged by SH heparin. Factor VIII activity was significantly lower in the LMW heparin group as compared to the standard heparin group after 18, 24, and 30 weeks. Antithrombin III, fibrinogen, fibrin monomers, plasminogen, and alpha 2-antiplasmin were comparable in both groups. Creatinine, urea, hemoglobin, and hematocrit were also unchanged, excluding differences in dialysis efficacy or occult blood loss. Equal numbers of blood transfusions were necessary, but bleeding complications did not occur in either group. In conclusion, safe and effective dialysis can be performed using this low molecular weight heparin for anticoagulation in hemodialysis and hemofiltration. The possible benefits of LMW heparin (reduced frequency of bleeding, alleviation of hypertriglyceridemia) were not, however, apparent, possibly because of the short observation period and the low incidence of hemorrhagic complications in routine dialyses.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011517 Prothrombin Time Clotting time of PLASMA recalcified in the presence of excess TISSUE THROMBOPLASTIN. Factors measured are FIBRINOGEN; PROTHROMBIN; FACTOR V; FACTOR VII; and FACTOR X. It is used for monitoring anticoagulant therapy with COUMARINS. Quick Test,Russell's Viper Venom Time,Thrombotest,Russell Viper Venom Time,Russells Viper Venom Time,Prothrombin Times,Test, Quick,Time, Prothrombin,Times, Prothrombin
D005260 Female Females
D005340 Fibrinogen Plasma glycoprotein clotted by thrombin, composed of a dimer of three non-identical pairs of polypeptide chains (alpha, beta, gamma) held together by disulfide bonds. Fibrinogen clotting is a sol-gel change involving complex molecular arrangements: whereas fibrinogen is cleaved by thrombin to form polypeptides A and B, the proteolytic action of other enzymes yields different fibrinogen degradation products. Coagulation Factor I,Factor I,Blood Coagulation Factor I,gamma-Fibrinogen,Factor I, Coagulation,gamma Fibrinogen
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006440 Hemofiltration Extracorporeal ULTRAFILTRATION technique without HEMODIALYSIS for treatment of fluid overload and electrolyte disturbances affecting renal, cardiac, or pulmonary function. Arteriovenous Hemofiltration,Venovenous Hemofiltration,Arteriovenous Hemofiltrations,Hemofiltration, Arteriovenous,Hemofiltration, Venovenous,Hemofiltrations,Venovenous Hemofiltrations
D006493 Heparin A highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from six to twenty thousand. Heparin occurs in and is obtained from liver, lung, mast cells, etc., of vertebrates. Its function is unknown, but it is used to prevent blood clotting in vivo and vitro, in the form of many different salts. Heparinic Acid,alpha-Heparin,Heparin Sodium,Liquaemin,Sodium Heparin,Unfractionated Heparin,Heparin, Sodium,Heparin, Unfractionated,alpha Heparin
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight

Related Publications

J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis.
January 2002, Nephron,
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin.
January 1991, ASAIO transactions,
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
[Standard heparin versus low-molecular-weight heparin].
January 1999, Wiener medizinische Wochenschrift (1946),
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Comparison of low molecular weight heparin and standard heparin in hemodialysis.
January 1990, ASAIO transactions,
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients.
January 2006, Renal failure,
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Low molecular weight heparin in diabetic and nondiabetic hypercholesterolemic patients receiving long-term hemodialysis.
January 1998, Journal of the Formosan Medical Association = Taiwan yi zhi,
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
[Instantaneous clearances: standard heparin versus low molecular weight heparin].
December 1994, Minerva urologica e nefrologica = The Italian journal of urology and nephrology,
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Long-term use of low-molecular-weight heparin in hemodialysis patients: a 7-year experience.
January 2009, Blood purification,
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Long-term use of low molecular weight heparin ameliorates hyperlipidemia in patients on hemodialysis.
January 1992, ASAIO journal (American Society for Artificial Internal Organs : 1992),
J Schrader, and W Stibbe, and M Kandt, and G Warneke, and V Armstrong, and H J Müller, and F Scheler
Long-term effects of low molecular weight heparin on lipid parameters in hemodialysis patients.
September 1996, International angiology : a journal of the International Union of Angiology,
Copied contents to your clipboard!